Postmeiotic segregation increased 2 (PMS2) IVD, antibody

Postmeiotic segregation increased 2 (PMS2) IVD antibody tests detect the presence or levels of PMS2 protein in clinical samples, helping identify defects in DNA mismatch repair. These tests are primarily used in cancer diagnostics, particularly for hereditary non-polyposis colorectal cancer (HNPCC) and Lynch syndrome screening, where PMS2 mutations are linked to tumor development.

These devices are typically in-vitro diagnostics (IVDs) regulated under strict clinical performance standards, often requiring validation for accuracy and reliability. They may be supplied as reagents, kits, or ready-to-use formats, depending on the intended use and laboratory workflow, with classification varying by jurisdiction based on risk and diagnostic purpose.